221 related articles for article (PubMed ID: 11956588)
1. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer.
Wu XX; Kakehi Y; Mizutani Y; Kamoto T; Kinoshita H; Isogawa Y; Terachi T; Ogawa O
Int J Oncol; 2002 May; 20(5):949-54. PubMed ID: 11956588
[TBL] [Abstract][Full Text] [Related]
2. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
Kang J; Bu J; Hao Y; Chen F
Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of human renal cell carcinoma cell lines to TRAIL-induced apoptosis by anthracyclines.
Wu XX; Ogawa O; Kakehi Y
Int J Urol; 2004 Mar; 11(3):164-70. PubMed ID: 15009365
[TBL] [Abstract][Full Text] [Related]
4. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
Munshi A; McDonnell TJ; Meyn RE
Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
7. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
[TBL] [Abstract][Full Text] [Related]
8. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Voelkel-Johnson C; King DL; Norris JS
Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
[TBL] [Abstract][Full Text] [Related]
9. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
Shankar S; Singh TR; Srivastava RK
Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
[TBL] [Abstract][Full Text] [Related]
10. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
Rokhlin OW; Guseva NV; Tagiyev AF; Glover RA; Cohen MB
Prostate; 2002 Jun; 52(1):1-11. PubMed ID: 11992615
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP.
Jeon KI; Rih JK; Kim HJ; Lee YJ; Cho CH; Goldberg ID; Rosen EM; Bae I
FEBS Lett; 2003 Jun; 544(1-3):246-51. PubMed ID: 12782325
[TBL] [Abstract][Full Text] [Related]
15. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE
Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339
[TBL] [Abstract][Full Text] [Related]
16. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells.
Szliszka E; Helewski KJ; Mizgala E; Krol W
Int J Oncol; 2011 Oct; 39(4):771-9. PubMed ID: 21743964
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.
Yu R; Mandlekar S; Ruben S; Ni J; Kong AN
Cancer Res; 2000 May; 60(9):2384-9. PubMed ID: 10811114
[TBL] [Abstract][Full Text] [Related]
18. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells.
Sun SY; Yue P; Lotan R
Oncogene; 2000 Sep; 19(39):4513-22. PubMed ID: 11002424
[TBL] [Abstract][Full Text] [Related]
19. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Voelkel-Johnson C
Cancer Biol Ther; 2003; 2(3):283-90. PubMed ID: 12878867
[TBL] [Abstract][Full Text] [Related]
20. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
Tong X; Li H
Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]